Melanotan II Reconstitution: Measurement Education and What Studies Used

Searches about reconstituting a melanotan II vial are usually asking a measurement question rather than a pharmacology question: what does the label mass mean, what does adding solvent do to it, and how do the marks on a small syringe relate to volume? This page answers the measurement half only. It is written in the third person, it describes what published papers reported, and it does not name a quantity for any reader. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

What "reconstitution" means

Reconstitution is the act of adding a liquid solvent to a lyophilised (freeze-dried) solid so that the solid dissolves and becomes a solution of a known concentration. Research peptides, including melanotan II (also written MT-II or MTII), are commonly supplied as a dry cake or a thin film inside a sealed glass vial, because peptides in the dry state are generally more chemically stable than peptides sitting in water. The dry state, however, has no concentration at all. Concentration only exists once a measured volume of solvent has been added.

Three separate quantities are involved, and conflating them is the most common source of confusion:

• Mass — the amount of peptide stated on the vial label or certificate of analysis, expressed in milligrams.
• Volume — the amount of solvent added to the vial, expressed in millilitres.
• Concentration — mass per unit volume, expressed in milligrams per millilitre, which is a property of the resulting solution rather than of the vial.

Adding solvent does not change the mass in the vial. It only changes how that mass is distributed through a volume of liquid. A vial with the same label mass can therefore yield very different concentrations depending on how much solvent was added, which is exactly why the arithmetic matters in a laboratory record.

The concentration equation

The relationship is fixed and can be written with symbols instead of numbers, which keeps it general:

Two consequences follow directly from that division. First, increasing V while holding M constant lowers C, and decreasing V raises C; the relationship is inverse, not additive. Second, if a laboratory record expresses amounts in micrograms rather than milligrams, a unit conversion is required before the division is meaningful, because one milligram equals one thousand micrograms. Most arithmetic errors in reconstitution worksheets are unit-conversion errors rather than division errors.

The reverse calculation — working out what volume of a solution contains a given mass — is the same equation rearranged: volume equals mass divided by concentration. PeptideU hosts a reconstitution calculator that performs this algebra as a lab-math exercise; it is a unit-conversion tool for reading the literature and nothing more, and it does not suggest a quantity for any person.

How syringe unit markings relate to millilitres

Small-volume syringes of the insulin type are graduated in "units" rather than millilitres, and this is a frequent source of misreading. On a hundred-unit barrel, the full barrel corresponds to one millilitre of liquid, so each single unit mark corresponds to one hundredth of a millilitre. The mapping is purely volumetric:

The critical point is that a unit mark measures liquid volume, never peptide mass. The mass contained in any volume depends entirely on the concentration C that was created during reconstitution. Barrel sizes also differ — smaller barrels marked in fewer total units span a smaller maximum volume and give finer graduations — so the same numeral on two different syringes can represent two different volumes. Laboratory documentation therefore records volumes in millilitres and concentrations in mg/mL, and treats unit marks only as a reading scale.

Reading a certificate of analysis for vial contents

A certificate of analysis (COA) is the document that supports the M term in the equation above. Analytical COAs for research peptides typically report several distinct items, and each one answers a different question:

• Identity — usually mass spectrometry, comparing an observed molecular weight with the theoretical molecular weight of the sequence.
• Purity — usually a percentage by high-performance liquid chromatography (HPLC), reflecting how much of the detected material is the target peptide rather than related impurities.
• Peptide content versus gross mass — synthetic peptides are often salts and contain bound water and counterions (acetate or trifluoroacetate), so the net peptide content can be lower than the gross weighed mass. A COA that distinguishes "net peptide content" from "total mass" is describing two different values of M.
• Water content — residual moisture from lyophilisation, commonly measured by Karl Fischer titration.
• Batch or lot number and date — the link between the document and the physical vial.

Because the published studies cited below were conducted with characterised research-grade material, the analytical paperwork is what makes any stated laboratory concentration interpretable. A vial without a matching COA has a label mass but no independent evidence of identity, purity, or net content.

Solvent classes used in laboratory and pharmaceutical practice

Published methods sections name the vehicle in which a peptide was dissolved, and readers of the primary literature are best served by checking that specific methods section rather than assuming a universal solvent. Broadly, the solvent classes that appear in pharmaceutical and preclinical practice are:

• Sterile water for injection — an unpreserved aqueous vehicle used where a solution is prepared and consumed within a single handling session.
• Bacteriostatic water — water containing a preservative (benzyl alcohol) intended to limit microbial growth in multi-entry vials.
• Sodium chloride injection (saline) — an isotonic aqueous vehicle widely used for parenteral preparations.
• Phosphate-buffered saline — a buffered aqueous vehicle common in preclinical and in vitro work where pH stability matters.
• Co-solvent and topical vehicles — organic co-solvents such as DMSO in cell-culture work, and cream or gel bases for dermal application. Researchers reported topical delivery of MTII in a preclinical melanoma model, where the study described topical therapy rather than a parenteral route (PMID 31968661).

Solvent choice interacts with stability: peptides in solution are generally less stable than lyophilised peptides, and pH, temperature, light exposure, freeze–thaw cycling and repeated vial entry are all variables that laboratory protocols control and document. Refrigerated storage of reconstituted solutions and protection from light are standard handling practices described for peptide solutions in research settings.

What the melanotan II studies administered

The verified literature for MTII is dominated by animal and preclinical work, which is relevant context for anyone trying to interpret concentration arithmetic: the numbers reported in those papers are species-specific research quantities, not human quantities.

In rodent work on body composition, researchers reported that peripherally administered MTII reduced fat mass in rats without invoking apoptosis, indicating a metabolic rather than a cytotoxic mechanism in that model (PMID 12834806). A separate rodent study examined the melanocortin agonist MT-II specifically in subcutaneous and visceral adipose tissue depots, reporting depot-level effects on adipose tissue (PMID 17567964). A behavioural study assessed whether acute and chronic administration of MTII produced aversive consequences, an important control question because reduced food intake can reflect malaise rather than a specific satiety effect (PMID 12704398). In the dermatological literature, the study on topical MTII reported suppression of melanoma in a preclinical model, with the authors describing PTEN upregulation and cyclooxygenase II inhibition as the mechanisms examined (PMID 31968661).

None of these papers establishes a human administration schedule, and this page does not translate animal quantities into human ones. Readers wanting the exact vehicle, route and quantity used in any of these experiments should consult the methods section of the original paper.

Melanotan II Safety: What Studies Report

The human-relevant signal in the verified literature comes from case reporting rather than controlled trials. A case report and literature review described renal infarction in association with melanotan II use, and the authors discussed melanotan II as a possible cause while reviewing previously published adverse events linked to the compound (PMID 31953620). Case reports establish temporal association rather than causation, but they are the principal published source of human adverse-event information for this peptide, and that paper also situates the case within the broader problem of unregulated, unanalysed injectable products.

In animals, the aversion study is the clearest reminder that measurable effects are not automatically benign effects: researchers explicitly tested whether the behavioural consequences of acute and chronic MTII administration included aversive components (PMID 12704398). Interpreting any reported effect therefore requires knowing both the species and the control conditions the study used.

Why the arithmetic is discussed separately from safety

Accurate mass-to-volume arithmetic tells a reader what a solution contains. It says nothing about whether that solution is appropriate, lawful, or safe for any person. The published record for melanotan II includes a documented serious vascular event in a case report (PMID 31953620) and animal findings whose translation to humans has not been established (PMID 17567964). Correct arithmetic and unknown clinical risk can coexist, and one does not resolve the other.

Regulatory context

Melanotan II is not an approved drug product in the United States and is not authorised as a medicine in the European Union; material offered for laboratory work is labelled research use only and is not manufactured to the standards required for human medicines. Regulators in several countries have issued public warnings about unapproved tanning peptides. Separately approved melanocortin-receptor products do exist — afamelanotide for a specific photodermatosis and bremelanotide for a specific sexual-desire indication — but they are distinct, approved, prescription products with their own labelling, and their approval does not extend to melanotan II. This paragraph states regulatory facts and is not legal advice.

Key takeaways

1. Reconstitution converts a labelled mass into a solution with a concentration; the vial itself has no concentration until solvent is added.
2. Concentration equals labelled mass divided by solvent volume, and the relationship is inverse: more solvent means a lower mg/mL figure.
3. Insulin-syringe unit marks measure volume only; on a hundred-unit barrel the full barrel equals one millilitre and a single mark equals one hundredth of a millilitre.
4. A certificate of analysis supports the mass term by reporting identity, HPLC purity, net peptide content, and water content by lot.
5. The verified melanotan II evidence base is mainly rodent and preclinical, with human adverse-event information coming from case reporting (PMID 31953620).

References

• Melanotan II: a possible cause of renal infarction: review of the literature and case report (CEN Case Reports, 2020)
• Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII (International Journal of Obesity and Related Metabolic Disorders, 2003)
• The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents (The Journal of Pharmacology and Experimental Therapeutics, 2007)
• Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition (International Journal of Molecular Sciences, 2020)
• MTII administered peripherally reduces fat without invoking apoptosis in rats (Physiology & Behavior, 2003)